Qol Holdings (3034) Q3 2026 earnings summary

Executive summary

• Achieved record-high net sales of ¥216,025 million for the nine months ended December 31, 2025, up 9.0% year-over-year, but operating and ordinary profits declined; profit attributable to owners of parent rose 32.6% to ¥4,671 million, driven by non-operating factors.

• EBITDA was ¥16,593 million, down 2.2% year-over-year.

• Pharmacy business saw higher sales but lower profit due to changes in prescription trends and fee structures.

• BPO Contracting Businesses delivered higher sales and profit, supported by increased demand for MR dispatches.

• Announced a medium-term management plan with a 2030 vision focused on healthcare, digital transformation, and ESG initiatives.

Financial highlights

• Net sales rose 9.0% year-over-year to ¥216,025 million for 3Q FY3/2026.

• Operating profit fell 14.7% to ¥9,415 million; ordinary profit dropped 16.5% to ¥9,487 million.

• Profit attributable to owners of parent increased 32.6% to ¥4,671 million.

• Basic earnings per share rose to ¥124.46 from ¥94.22 year-over-year.

• Dividend forecast for FY2026 is ¥46.00 per share, up from ¥34.00 in FY2025.

Outlook and guidance

• Full-year forecast targets ¥280,000 million in net sales and ¥15,500 million in operating profit, with profit attributable to owners of parent at ¥7,000 million.

• Progress rates as of 3Q: 77.2% for net sales, 60.7% for operating profit, and 66.7% for profit attributable to owners of parent.

• No changes to previously announced financial forecasts.